Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1–2 trial

ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing

(2021) Cecilia L. Moore et al.   BMC INFECTIOUS DISEASES

Are New Antiretroviral Treatments Increasing the Risk of Weight Gain?

(2021) Shahini Shah et al.   DRUGS

Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children

(2021) Anna Turkova et al.   NEW ENGLAND JOURNAL OF MEDICINE

Development of Dolutegravir Single-entity and Fixed-dose Combination Formulations for Children

(2021) Rajendra P. Singh et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial

(2020) Pauline D J Bollen et al.   Lancet HIV

Safety, Pharmacokinetics and Efficacy of Dolutegravir in Treatment-experienced HIV-1 Infected Adolescents

(2015) Rolando M. Viani et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

A sensitive HPLC–MS/MS method for the determination of dolutegravir in human plasma

(2013) Chantelle Bennetto-Hood et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

(2013) Pedro Cahn et al.   LANCET

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

(2013) Francois Raffi et al.   LANCET

Effect of Food on the Pharmacokinetics of the Integrase Inhibitor Dolutegravir

(2011) Ivy Song et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial

(2011) Jan van Lunzen et al.   LANCET INFECTIOUS DISEASES